Respiratory Syncytial Virus Infections
Pipeline by Development Stage
Drug Modality Breakdown
Respiratory is a $39.4B mature market dominated by established inhalers and combination therapies with significant patent cliff risk.
Key Trends
- Consolidation around GSK's triple-therapy franchises (Trelegy, Breo, Anoro)
- Major patent expirations 2026-2031 creating $7.8B revenue cliff
- High clinical trial activity (4,862 trials) suggesting pipeline innovation despite market maturity
Career Verdict
Respiratory offers stable commercial careers but limited growth upside; best for professionals seeking established markets with strong commercial infrastructure rather than innovation-driven advancement.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 46% | Launch | Growing | 15.0yr |
| 2 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 19% | Peak | Stable | |
| 3 | TRELEGY ELLIPTA (fluticasone/umeclidinium/vilanterol) | GSK | $4.5B | 11% | Peak | Declining | 4.9yr |
| 4 | CREON (pancrelipase) | AbbVie | $1.5B | 4% | Approaching LOE | Declining | |
| 5 | BREO ELLIPTA (fluticasone/vilanterol) | GSK | $1.4B | 4% | Peak | Declining | 4.9yr |
Drug Class Breakdown
dominant market driver
fragmented portfolio
rapidly expanding
legacy product
patent cliff approaching
mature maintenance therapy
Career Outlook
StableRespiratory is a stable, mature market suitable for commercial and medical affairs professionals seeking established career paths, but offers limited growth or innovation-focused opportunities. The impending patent cliff ($7.8B+ revenue at risk 2026-2031) will drive near-term restructuring and consolidation, potentially reducing headcount in 2027-2028. Professionals should expect strong compensation in Medical Affairs and field roles but limited advancement into strategic or R&D positions.
Breaking In
New graduates should prioritize commercial, field-based, or Medical Affairs roles over R&D; respiratory offers structured training and stable compensation but limited innovation exposure, so pair this experience with cross-therapeutic skill-building for long-term mobility.
For Experienced Professionals
Experienced professionals should evaluate whether to maximize earnings in this mature, stable market or transition to higher-growth areas (oncology, cell therapy); respiratory consolidation 2027-2030 will reduce senior-level opportunities, so consider strategic moves before patent cliff impacts headcount.
In-Demand Skills
Best For
Hiring Landscape
The respiratory sector shows modest hiring momentum (510 jobs across tracked positions) concentrated in commercial and engineering roles, with AstraZeneca and GSK leading. Medical Affairs positions command premium salaries ($314K avg) but represent only 3% of openings, reflecting the mature market's focus on sales execution over innovation. Hiring velocity is moderate and reflects market consolidation rather than expansion, suggesting limited career progression opportunities for early-to-mid career professionals.
Top Hiring Companies
By Department
Respiratory hiring favors commercial and field-based roles over R&D; Medical Affairs roles offer premium compensation but are scarce, making this area competitive for specialized talent.
On Market (1)
Approved therapies currently available
Competitive Landscape
31 companies ranked by most advanced pipeline stage
+1 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 58,062 patients across 50 trials
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above
Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections
A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab
Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above
MVA-BN-RSV Vaccine Trial
A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age
A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above
A Dose Finding Study of VN-0200
Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract
Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study
Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults
Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients
A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection
RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
Viral Inhibition in Children for Treatment of RSV
Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women
Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women
RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.
RSV F Dose-Ranging Study in Women
Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)
Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus
A Study of BLB-201 RSV Vaccine in Infants and Children
A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study
A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.
Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension
Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children
Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults
A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants
A Study of XW001 in Healthy Adult Subjects
Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers
Pharmacokinetics and Safety of RV521 Formulations
Related Jobs in Respiratory
Medical Device Sales Associate Territory Account Manager
Compliance Specialist (Risk Assessment)
Key Account Manager-2
QA Manager - Computerized Systems Validation (CSV), befristet für 1 Jahr
U.S. Director of Medical Affairs (US DMA), COPD
Klinischer Anwendungsspezialist (m/w/d) Region Köln
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.